uploads///Chart

Johnson & Johnson’s Pharmaceuticals Business in 4Q17

By

Jan. 31 2018, Updated 7:34 a.m. ET

Pharmaceuticals business

Johnson & Johnson (JNJ) reported ~48.0% of its total revenues from the Pharmaceuticals business during 4Q17, making it the company’s largest revenue contributor.

JNJ’s Pharmaceuticals business includes revenues from the following franchises: oncology, cardiovascular and metabolics, infectious disease, immunology, neuroscience, and pulmonary hypertension. The chart below compares the revenues for the various franchises for the Pharmaceuticals segment since 1Q16.

Article continues below advertisement

Immunology franchise

Johnson & Johnson’s (JNJ) immunology franchise reported 5.1% growth in revenues to ~$3.1 billion during 4Q17, compared to ~$2.9 billion during 4Q16.

The franchise’s increase in revenues was driven by ~23.0% growth in Stelara sales and ~15.0% growth in Simponi/Simponi Aria sales. Its revenues were partially offset by a 9.7% decline in Remicade revenues.

Infectious disease franchise

JNJ’s infectious disease franchise reported 5.1% growth in revenues to $800.0 million during 4Q17, compared to $761.0 million in 4Q16. This increase in revenues was driven by ~16.4% growth in Edurant sales and ~5.1% growth in Prezista/Prezcobix sales. The revenue increase was partially offset by the decline in sales of other products.

Article continues below advertisement

Neuroscience franchise

JNJ’s neuroscience franchise reported 3.7% growth in revenues to $1.52 billion during 4Q17, compared to $1.47 billion during 4Q16. The increase in revenues was driven by ~18.5% growth in Invega Sustenna sales. This increase was substantially offset by lower sales of Concerta, Risperdal Consta, and other neuroscience products.

Oncology franchise

Johnson & Johnson’s oncology franchise reported 39.5% growth in revenues to ~$2.0 billion during 4Q17 compared to ~$1.5 billion during 4Q16. This increase in revenues was driven by ~85.5% growth in Darzalex sales, ~50.9% growth in Imbruvica sales, and ~45.5% growth in Zytiga sales. This revenue increase was partially offset by lower sales of other products.

Article continues below advertisement

Cardiovascular and metabolics products

Johnson & Johnson’s cardiovascular and metabolics franchise reported 1.2% growth in revenues to $1.62 billion during 4Q17 compared to $1.60 billion during 4Q16. This increase in revenues was driven by ~18.7% growth in Xarelto sales and ~10.1% growth in the sales of other products. The increase was substantially offset by lower sales of Procrit and Invokana.

Pulmonary hypertension products

Johnson & Johnson’s (JNJ) total revenues from pulmonary hypertension products totaled $610.0 million during 4Q17. This franchise’s products include Opsumit, Tracleer, and Uptravi. The franchise was acquired from Actelion in 2Q17.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 4.1% of its total investments in Johnson & Johnson (JNJ), 4.5% in Merck & Co. (MRK), 4.1% in Bristol-Myers Squibb (BMY), and 4.2% in Pfizer (PFE).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.